LB953 Cure rate of curettage alone for basal cell carcinoma

The purpose of this study was to demonstrate the effectiveness curettage alone for treatment basal cell carcinoma (BCC). We conducted a prospective single center examining cure rate 305 BCCs from 218 unique patients with follow up at least 3 years. After excluding deceased and those without clinical follow-up, 99.6% showed no recurrence after year (95% CI: 97.8%, 100.0%), 99.0% three years 96.5%, 99.9%). To best our knowledge, is first efficacy as BCC provides evidence support use modality.